Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
However, their safety and efficacy in pregnancy require more research to determine optimal use in fertility treatments and assisted reproduction technologies (ART)
February 2012
Lean mass loss during GLP-1 therapy is a real phenomenon, though the proportion varies by individual, drug, and habits
Clinical Safety Screens Performed MTC personal AND family history in the comorbidity multi-select MEN-2 personal AND family history separately Substance / opioid screen with three-month opiate window + free-text dose, frequency, dates Suicidality and recent suicide attempt as exclusionary opt-out Active cancer treatment and cancer-free-for-five-years exclusionary End-stage kidney and liver disease opt-out Severe GI screen (gastroparesis, blockage, IBD) Pancreatitis history in the multi-select Self-reported blood pressure range and resting heart rate Past 2-month GLP-1 use (semaglutide / tirzepatide / none) No validated PHQ-2 or PHQ-9 depression instrument suicidality is captured as a binary exclusionary opt-out and severe depression is a checkbox on the comorbidity multi-select, but the validated brief screening scale is not used
